1
|
Thivat E, Chanchou M, Mathieu S, Levesque S, Billoux T, Auzeloux P, Sas N, Molnar I, Jouberton E, Rouanet J, Fois G, Maigne L, Galmier MJ, Penault-Llorca F, Miot-Noirault E, Durando X, Cachin F. Assessment of 99mTc-NTP 15-5 uptake on cartilage, a new proteoglycan tracer: Study protocol for a phase I trial (CARSPECT). Front Med (Lausanne) 2022; 9:993151. [PMID: 36314021 PMCID: PMC9596979 DOI: 10.3389/fmed.2022.993151] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2022] [Accepted: 08/11/2022] [Indexed: 11/21/2022] Open
Abstract
Background 99mTc-NTP 15-5 is a SPECT radiotracer targeting proteoglycans (PG), components of the cartilaginous extracellular matrix. Imaging of PGs would be useful for the early detection of cartilage disorders (osteoarthritis, arthritis and chondrosarcoma, Aromatase Inhibitor associated arthralgia (AIA) in breast cancer), and the follow-up of patients under treatment. According to preclinical study results, 99mTc-NTP 15-5, is a good candidate for a specific functional molecular imaging of joints. We intend to initiate a first in-human study to confirm and quantify 99mTc-NTP 15-5 uptake in healthy joints. Methods As the clinical development of this radiotracer would be oriented toward the functional imaging of joint pathologies, we have chosen to include patients with healthy joints (unilateral osteoarthritis of the knee or breast cancer with indication of AI treatment). This phase I study will be an open-label, multicenter, dose-escalation trial of a radiopharmaceutical orientation to determine the recommended level of activity of 99mTc-NTP 15-5 to obtain the best joint tracer contrasts on images, without dose limiting toxicity (DLT). The secondary objectives will include the study of the pharmacology, biodistribution (using planar whole body and SPECT-CT acquisitions), toxicity, and dosimetry of this radiotracer. The dose escalation with 3 activity levels (5, 10, and 15 MBq/kg), will be conditioned by the absence at the previous level of DLT and of a visualized tracer accumulation on more than 80% of healthy joints as observed on scintigraphy performed at ≤ 2 h post-injection. Discussion This first in-human phase I trial will be proof-of-concept of the relevance of 99mTc-NTP 15-5 as a cartilage tracer, with the determination of the optimal methodology (dose and acquisition time) to obtain the best contrast to provide a functional image of joints with SPECT-CT. Trial registration number Clinicaltrials.gov: NCT04481230. Identifier in French National Agency for the Safety of Medicines and Health Products (ANSM): N°EudraCT 2020-000495-37.
Collapse
Affiliation(s)
- Emilie Thivat
- Institut National de la Santé et de la Recherche Médicale (INSERM) U1240 Imagerie Moléculaire et Stratégies Theranostiques (IMoST), Université Clermont Auvergne, Clermont-Ferrand, France,Département de Recherche Clinique, Centre Jean PERRIN, Clermont-Ferrand, France,Centre d'Investigation Clinique UMR501, Clermont-Ferrand, France,*Correspondence: Emilie Thivat
| | - Marion Chanchou
- Institut National de la Santé et de la Recherche Médicale (INSERM) U1240 Imagerie Moléculaire et Stratégies Theranostiques (IMoST), Université Clermont Auvergne, Clermont-Ferrand, France,Service de Médecine Nucléaire, Centre Jean PERRIN, Clermont-Ferrand, France
| | - Sylvain Mathieu
- Service de Rhumatologie, Centre Hospitalier Universitaire (CHU) Gabriel Montpied, Université Clermont-Auvergne, Clermont-Ferrand, France
| | - Sophie Levesque
- Institut National de la Santé et de la Recherche Médicale (INSERM) U1240 Imagerie Moléculaire et Stratégies Theranostiques (IMoST), Université Clermont Auvergne, Clermont-Ferrand, France,Département de Recherche Clinique, Centre Jean PERRIN, Clermont-Ferrand, France,Unité de Radiopharmacie, Centre Jean PERRIN, Clermont-Ferrand, France
| | - Tommy Billoux
- Institut National de la Santé et de la Recherche Médicale (INSERM) U1240 Imagerie Moléculaire et Stratégies Theranostiques (IMoST), Université Clermont Auvergne, Clermont-Ferrand, France,Service de Physique Médicale, Centre Jean PERRIN, Clermont-Ferrand, France
| | - Philippe Auzeloux
- Institut National de la Santé et de la Recherche Médicale (INSERM) U1240 Imagerie Moléculaire et Stratégies Theranostiques (IMoST), Université Clermont Auvergne, Clermont-Ferrand, France
| | - Nicolas Sas
- Institut National de la Santé et de la Recherche Médicale (INSERM) U1240 Imagerie Moléculaire et Stratégies Theranostiques (IMoST), Université Clermont Auvergne, Clermont-Ferrand, France,Service de Physique Médicale, Centre Jean PERRIN, Clermont-Ferrand, France
| | - Ioana Molnar
- Institut National de la Santé et de la Recherche Médicale (INSERM) U1240 Imagerie Moléculaire et Stratégies Theranostiques (IMoST), Université Clermont Auvergne, Clermont-Ferrand, France,Département de Recherche Clinique, Centre Jean PERRIN, Clermont-Ferrand, France,Centre d'Investigation Clinique UMR501, Clermont-Ferrand, France
| | - Elodie Jouberton
- Institut National de la Santé et de la Recherche Médicale (INSERM) U1240 Imagerie Moléculaire et Stratégies Theranostiques (IMoST), Université Clermont Auvergne, Clermont-Ferrand, France,Service de Médecine Nucléaire, Centre Jean PERRIN, Clermont-Ferrand, France
| | - Jacques Rouanet
- Institut National de la Santé et de la Recherche Médicale (INSERM) U1240 Imagerie Moléculaire et Stratégies Theranostiques (IMoST), Université Clermont Auvergne, Clermont-Ferrand, France,Service de Dermatologie et d'Oncologie Cutanée, Centre Hospitalier Universitaire (CHU) Clermont-Ferrand, Clermont-Ferrand, France
| | - Giovanna Fois
- Laboratoire de Physique de Clermont, UMR6533, Centre National de la Recherche Scientifique (CNRS)/Institut National de Physique Nucléaire et de Physique des Particules (IN2P3), Université Clermont Auvergne, Clermont-Ferrand, France
| | - Lydia Maigne
- Laboratoire de Physique de Clermont, UMR6533, Centre National de la Recherche Scientifique (CNRS)/Institut National de Physique Nucléaire et de Physique des Particules (IN2P3), Université Clermont Auvergne, Clermont-Ferrand, France
| | - Marie-Josephe Galmier
- Institut National de la Santé et de la Recherche Médicale (INSERM) U1240 Imagerie Moléculaire et Stratégies Theranostiques (IMoST), Université Clermont Auvergne, Clermont-Ferrand, France
| | - Frédérique Penault-Llorca
- Institut National de la Santé et de la Recherche Médicale (INSERM) U1240 Imagerie Moléculaire et Stratégies Theranostiques (IMoST), Université Clermont Auvergne, Clermont-Ferrand, France,Centre d'Investigation Clinique UMR501, Clermont-Ferrand, France,Département de Biopathologie, Centre Jean PERRIN, Clermont-Ferrand, France
| | - Elisabeth Miot-Noirault
- Institut National de la Santé et de la Recherche Médicale (INSERM) U1240 Imagerie Moléculaire et Stratégies Theranostiques (IMoST), Université Clermont Auvergne, Clermont-Ferrand, France
| | - Xavier Durando
- Institut National de la Santé et de la Recherche Médicale (INSERM) U1240 Imagerie Moléculaire et Stratégies Theranostiques (IMoST), Université Clermont Auvergne, Clermont-Ferrand, France,Département de Recherche Clinique, Centre Jean PERRIN, Clermont-Ferrand, France,Centre d'Investigation Clinique UMR501, Clermont-Ferrand, France,Département d'oncologie Médicale, Centre Jean PERRIN, Clermont-Ferrand, France
| | - Florent Cachin
- Institut National de la Santé et de la Recherche Médicale (INSERM) U1240 Imagerie Moléculaire et Stratégies Theranostiques (IMoST), Université Clermont Auvergne, Clermont-Ferrand, France,Centre d'Investigation Clinique UMR501, Clermont-Ferrand, France,Service de Médecine Nucléaire, Centre Jean PERRIN, Clermont-Ferrand, France
| |
Collapse
|
3
|
Li ZQ, Zhang YY, Zheng YJ, Li B, Wu GP. Insights into Thiourea-Based Bifunctional Catalysts for Efficient Conversion of CO2 to Cyclic Carbonates. J Org Chem 2022; 87:3145-3155. [DOI: 10.1021/acs.joc.1c02888] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Zhuo-Qun Li
- College of Material, Chemistry and Chemical Engineering, Key Laboratory of Organosilicon Chemistry and Material Technology, Ministry of Education, Hangzhou Normal University, Hangzhou 310036, China
| | - Yao-Yao Zhang
- MOE Key Laboratory of Macromolecular Synthesis and Functionalization, and Key Laboratory of Adsorption and Separation Materials & Technologies of Zhejiang Province, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou 310027, China
| | - Yu-Jia Zheng
- College of Material, Chemistry and Chemical Engineering, Key Laboratory of Organosilicon Chemistry and Material Technology, Ministry of Education, Hangzhou Normal University, Hangzhou 310036, China
| | - Bo Li
- College of Material, Chemistry and Chemical Engineering, Key Laboratory of Organosilicon Chemistry and Material Technology, Ministry of Education, Hangzhou Normal University, Hangzhou 310036, China
| | - Guang-Peng Wu
- MOE Key Laboratory of Macromolecular Synthesis and Functionalization, and Key Laboratory of Adsorption and Separation Materials & Technologies of Zhejiang Province, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou 310027, China
| |
Collapse
|
4
|
Szczęśniak-Sięga BM, Wiatrak B, Czyżnikowska Ż, Janczak J, Wiglusz RJ, Maniewska J. Synthesis and biological evaluation as well as in silico studies of arylpiperazine-1,2-benzothiazine derivatives as novel anti-inflammatory agents. Bioorg Chem 2020; 106:104476. [PMID: 33250206 DOI: 10.1016/j.bioorg.2020.104476] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2020] [Revised: 11/06/2020] [Accepted: 11/12/2020] [Indexed: 12/20/2022]
Abstract
Novel arylpiperazine-1,2-benzothiazine derivatives have been designed and synthesized as potential anti-inflammatory agents. Their structure and properties have been studied using spectroscopic techniques (1H NMR, 13C NMR, FT-IR), MS, elemental analyses, and single-crystal X-ray diffraction (SCXRD, for compound 7b). This study aimed to evaluate the inhibitory activity of new derivatives against both cyclooxygenase isoforms COX-1 and COX-2 due to the similarity of new compounds to oxicams drugs from the NSAIDs group. All new compounds were divided into two series - A and B - with a different linker between thiazine and piperazines nitrogens. Series A included the three-carbon aliphatic linker and series B - two-carbon with a carbonyl group. According to in vitro and molecular docking studies all new compounds exhibited cyclooxygenase inhibitory activity. The series of A compounds included COX-1 inhibitors only. In contrast, the B series showed inhibition of both COX-1 and COX-2, which suggested the importance of the acetoxy linker for COX-2 inhibition. Moreover, the most selective compound 7b, towards COX-2, was non-toxic for the normal human cell line (in concentration of 10 µM) comparable to reference drug meloxicam. Additionally, investigation of influence on model membranes confirmed the ability of the compound 7b to penetrate lipid bilayers which seemed to be important to the influence with membrane protein-cyclooxygenase.
Collapse
Affiliation(s)
- Berenika M Szczęśniak-Sięga
- Department of Medicinal Chemistry, Faculty of Pharmacy, Wroclaw Medical University, Borowska 211, 50-556 Wrocław, Poland.
| | - Benita Wiatrak
- Department of Pharmacology, Faculty of Medicine, Wroclaw Medical University, J. Mikulicza-Radeckiego 2, 50-345 Wrocław, Poland; Department of Basic Medical Sciences, Faculty of Pharmacy, Wroclaw Medical University, Borowska 211, 50-556 Wroclaw, Poland
| | - Żaneta Czyżnikowska
- Department of Inorganic Chemistry, Faculty of Pharmacy, Wroclaw Medical University, Borowska 211a, 50-556 Wrocław, Poland
| | - Jan Janczak
- Institute of Low Temperature and Structure Research, Polish Academy of Sciences, Okólna 2 Str., 50-422 Wrocław, Poland
| | - Rafal J Wiglusz
- Institute of Low Temperature and Structure Research, Polish Academy of Sciences, Okólna 2 Str., 50-422 Wrocław, Poland
| | - Jadwiga Maniewska
- Department of Medicinal Chemistry, Faculty of Pharmacy, Wroclaw Medical University, Borowska 211, 50-556 Wrocław, Poland
| |
Collapse
|
5
|
Gouda MA, Hussein BHM, El-Said Sherif Y. Synthesis and medicinal importance of oxicams and their analogues. SYNTHETIC COMMUN 2017. [DOI: 10.1080/00397911.2017.1350983] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- Moustafa A. Gouda
- Department of Chemistry, Faculty of Science and Arts, Taibah University, Ulla, Kingdom of Saudi Arabia
- Department of Chemistry, Faculty of Science, Mansoura University, Mansoura, Egypt
| | - Belal H. M. Hussein
- Department of Chemistry, Faculty of Science and Arts, Taibah University, Ulla, Kingdom of Saudi Arabia
- Department of Chemistry, Faculty of Science, Suez Canal University, Ismailia, Egypt
| | - Yousery El-Said Sherif
- Department of Chemistry, Faculty of Science and Arts, Taibah University, Ulla, Kingdom of Saudi Arabia
- Department of Clinical Pharmacology, Faculty of Medicine, Mansoura University, Mansoura, Egypt
| |
Collapse
|